Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.69 (
BMT
)
2,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To study the impact of an MHC class II-negative environment on T cell immune reconstitution, we have analyzed the phenotypical and functional characteristics of FACS-sorted cultured CD4(+) and CD8(+) T cells in two
Bare Lymphocyte Syndrome
(
BLS
) patients before and after allo-
BMT
. A similar analysis was performed in two MHC class II expressing pediatric leukemia patients after treatment with an allo-
BMT
who were included in our study as control. It was observed that CD4(+) T cells displayed cytolytic alloreactivity in both
BLS
patients prior to and within the first year after allo-
BMT
, whereas such cells were absent at a later time-point, in the donors and pediatric leukemia controls. In addition, reduced MHC class II expression was observed in CD8(+) T cells of both recipients early after allo-
BMT
, irrespective of the T cell chimerism pattern. Lack of endogenous MHC class II expression in
BLS
patients, therefore, results in aberrant T cell selection within the first year after allo-
BMT
, analogous to T cell selection before transplantation. These T cell selection processes seem to be normalized at a later time point after allo-
BMT
probably due to migration and integration of graft-derived MHC class II-positive antigen presenting cells to sites of T cell selection.
...
PMID:T cell immune reconstitution after allogeneic bone marrow transplantation in bare lymphocyte syndrome. 1105 33